UCB SA stock gains momentum as JPMorgan notes strong EPS growth prospects

Published 21/08/2024, 09:14
UCB SA stock gains momentum as JPMorgan notes strong EPS growth prospects

On Wednesday, JPMorgan shifted its stance on UCB SA (Euronext Brussels: UCB) (OTC: UCBJY) stock, upgrading the pharmaceutical company from Neutral to Overweight. The firm also increased UCB's price target to €200.00, up from the previous €150.00. This decision comes in the wake of UCB's shares climbing by 22% since the beginning of June.

The analyst from JPMorgan highlighted UCB's growth potential, noting an expected compound annual growth rate (CAGR) in earnings per share (EPS) of 31% from 2024 to 2027.

This rate surpasses the projected growth for the European MidCap Pharma/Biotech Sector, which is estimated at 19% for 2025-2028, and 21% versus the sector's 14% for the same period. Despite the recent performance, the analyst believes that UCB's growth profile is still not fully appreciated by the market.

UCB's stock is currently trading at only 22 times the projected 2025 core EPS and 17 times the 2026 estimate, which is considered low compared to the sector averages of 17 times and 14 times, respectively.

The analyst expects that the de-risking of UCB's growth, particularly with the anticipated U.S. approval of additional uses for the drug Bimzelx and its subsequent launch for Hidradenitis Suppurativa (HS), will propel the shares in the next 12 to 18 months.

Furthermore, the JPMorgan analyst pointed out that while much of UCB's pipeline is considered high risk and is not currently factored into market valuations, upcoming decisions on the further development of Atopic Dermatitis treatments UCB9741 and UCB1381 could provide additional growth.

These potential developments have not been included in current forecasts but could extend the duration of UCB's growth and lead to future upgrades, thus contributing to the stock's performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.